# How Should Clinics Measure Prior Authorization Denial Metrics in 2026?

getpulse.care · September 26, 2026

> Prior authorization denial metrics should measure more than the percentage of requests denied. For a clinic or care network, the useful dashboard...

Prior authorization denial metrics should measure more than the percentage of requests denied. For a clinic or care network, the useful dashboard separates initial approvals, denials, incomplete submissions, peer-to-peer reviews, formal appeals, overturns, turnaround time, administrative burden, and patient consequences. Recent reporting based on newly available insurer data indicates that denial rates vary widely by insurer and service category, with KFF reporting that some insurers denied approximately 12% to 18% of measured prior authorization requests in 2025. That range should not be treated as a universal benchmark or as proof that every organization is performing poorly. The direct answer is to establish a consistent denominator, classify every decision consistently, segment results by payer and request type, and connect outcomes to financial and operational effects.

## What Prior Authorization Denial Metrics Actually Show

**Also worth reading:** [How Do Prior Authorization Analytics Improve Care Coordination Without Adding More Administrative Work?](https://getpulse.care/knowledge/how_do_prior_authorization_analytics_improve_care_coordination_without_adding_more_administrative_work.php) · [What is the true cost of prior authorization automation in 2026 for healthcare networks?](https://getpulse.care/knowledge/what_is_the_true_cost_of_prior_authorization_automation_in_2026_for_healthcare_networks.php) · [Which EHR Pilot Success Metrics Should Care Organizations Measure Before Scaling in 2026?](https://getpulse.care/knowledge/which_ehr_pilot_success_metrics_should_care_organizations_measure_before_scaling_in_2026.php)

A prior authorization denial metric records that a payer did not approve a utilization-management request within the applicable review process. It does not automatically establish that the request was medically unnecessary, that the payer acted unlawfully, or that the clinic can obtain approval simply by resubmitting it. A request can be denied for a coverage issue, missing documentation, coding mismatch, incorrect site of care, lack of medical necessity, or failure to satisfy a payer-specific rule. Those reasons require different responses, so a single “denied” total can conceal where the workflow is actually failing.

The primary metrics should include initial approval rate, initial denial rate, incomplete or administratively returned rate, appeal rate, appeal overturn rate, final denial rate, median and 90th-percentile turnaround time, and the share of denials resolved within each payer deadline. Turnaround time should be reported both from first submission to a decision and from the date of a complete submission to a decision. Mixing those clocks makes a clinic appear faster or slower than it really is. A credible program also reports authorization volume so that teams can distinguish a 10% denial rate on 20 requests from the same rate on 2,000 requests.

## How to Build a Reliable Prior Authorization Dashboard

Start by defining the unit of analysis as one unique authorization request rather than one claim, document, fax page, or staff interaction. Create a key that links the patient, authorization number, payer, provider, service or drug, submission date, decision date, and any subsequent appeal. Then document which state the case reaches: submitted, rejected for missing information, pended, peer-to-peer requested, denied, appealed, approved on appeal, or finally denied. Staff should be able to select the same reason codes for the same events, while a data steward periodically audits a sample against source records.

The denominator must match the numerator. A raw denial rate is normally calculated as denials divided by all authorization requests reaching a payer decision during the reporting period. A separate administrative return rate should use all submitted requests, because some requests never reach a clinical denial decision. The dashboard should also distinguish requests that were outside coverage from those denied after payer review. For a care network, results should be filterable by facility, specialty, clinician, service line, urgency, delegated vendor, and payer, but small groups should be suppressed or pooled to avoid identifying patients.

## Useful Benchmarks and Thresholds in 2026

Recent public reporting adds useful context, but it does not provide a universal target. KFF reported insurer denial rates ranging from roughly 12% to 18% among the plans included in its 2025 analysis. The spread is more informative than the midpoint: it suggests that payer-specific performance, service mix, plan rules, data completeness, and measurement design can materially change the result. A network sitting above that range should investigate the composition of its requests before concluding that its submission quality is weak. A network below it should still examine appeal overturn rates, delayed approvals, and patient abandonment.

A practical internal alert can be based on movement rather than an arbitrary industry number. Investigate a payer’s denial rate when it rises by at least 5 percentage points over a rolling quarter, exceeds the network baseline by 5 points for two consecutive periods, or changes by 20% relative to its own history. The 90th-percentile decision time should be watched for breaches rather than only the average, because a low median can hide severe delays. Monthly volume should be reviewed for unusual increases of 20% or more, while individual cases should be escalated immediately when a clinical deadline is approaching, treatment cannot safely wait, or a denial appears to involve an urgent service.

| Feature | Basic denial report | Operational prior authorization scorecard |
| --- | --- | --- |
| Measures | Denials divided by all decided requests | Approvals, returns, denials, appeals, overturns, final denials, time, and workload |
| Segmentation | Overall payer total | Payer, service, location, urgency, clinician group, and vendor |
| Timing | Average turnaround | Median, 90th percentile, aging cases, and deadline risk |
| Action | Quarterly summary | Weekly work queues, trend alerts, root-cause review, and payer follow-up |
| Patient effect | Usually absent | Abandonment, delayed treatment, out-of-pocket exposure, and complaint linkage |

## Why Denial Rates Are Not the Same as Appeal Performance
A high appeal overturn rate may indicate that the initial review was wrong, but it can also indicate that the clinic is appealing selectively or that certain request types have documentation problems. A low overturn rate does not necessarily mean that every denial was correct; appeals may be underused, incomplete, or abandoned. Clinics should therefore report the percentage of denials appealed, the number of appeals filed by the applicable deadline, the approval rate among appealed cases, and the number of unresolved appeals. They should also separate payer reconsideration from a true independent appeal, because the rights, deadlines, and evidence requirements can differ.

The strongest review process samples both upheld and overturned cases. For overturned denials, it checks whether the original submission omitted a payer-required document, used an incorrect code, failed to answer a clinical question, or was sent through the wrong channel. For upheld denials, staff confirm that coverage rules were checked before submission and that the record contains enough evidence for an appeal. The aim is not to maximize overturns through volume; it is to reduce preventable denials and correct errors that recur across a service line. A clinic that files thousands of appeals may achieve a good overturn rate while still imposing excessive labor and delaying care.

## Practical Steps for Reducing Preventable Denials

The first operational step is to prevent avoidable returns before submission. Create payer-specific checklists for imaging, procedures, medications, and high-cost therapies, and assign a named person to verify coverage, authorization requirements, frequency limits, documentation, and correct coding. Track the reason for every administrative return and the employee who resolved it. A five-percentage-point decline in missing-information returns can matter as much as a decline in clinical denials because those cases consume staff time without producing a substantive payer decision.

The second step is to make denials actionable. Standardize reason codes, route them to the appropriate clinical, coding, authorization, or benefits specialist, and attach a deadline to each case. For medical-necessity denials, the clinician should review the payer rationale and the available evidence before deciding whether to appeal, seek peer-to-peer review, or ask the patient about alternatives. For coding or coverage denials, a benefits specialist may resolve the issue more quickly than a clinician. Weekly aging reports should show not merely how many cases are open, but which ones lack a document, await payer action, need clinical review, or are ready for submission.

The third step is to measure corrections. Record whether an appeal was approved because new evidence was supplied, a code changed, a payer policy was clarified, or the payer reversed its decision without new information. This reveals whether prevention rules are working. Within 60 to 90 days, a service line should aim to reduce its highest-volume preventable reason code, not chase a one-month fluctuation in the overall rate. The dashboard should also monitor workload, because automation that reduces submissions but creates difficult rework may improve appearance rather than performance.

## Comparing Internal Tracking, Payer Data, and Vendor Analytics

Internal tracking, payer-published data, and vendor analytics answer different questions. Internal systems provide the most complete view of requests, staff effort, resubmissions, appeals, and final outcomes, but definitions may differ across facilities. Payer data can support benchmarking and may reveal plan-level patterns, but reporting rules, covered services, and missing cases can limit direct comparisons. A utilization-management vendor may add normalized reason codes and workflow data, but clinics should verify sample size, denominator rules, latency, and whether the vendor reports a submission as a denial before the payer issued a final decision.

No source should be accepted without a data dictionary. Confirm whether a request is counted once or multiple times, whether duplicate submissions are removed, what date determines the reporting period, and how pendings and withdrawals are classified. The site angle matters here: a B2B patient-pulse and care-coordination platform can connect authorization outcomes with operational and patient-experience signals, but it should not replace source systems or make unsupported predictions. A useful product exposes discrepancies, preserves audit trails, and gives clinics control over definitions. It should also meet privacy and security requirements, especially when patient-level or identifiable authorization data is used.

| Source | Strength | Common limitation | Best use |
| --- | --- | --- | --- |
| Clinic authorization system | Direct control of submissions, staff activity, and appeals | Inconsistent coding across sites | Daily operations and internal accountability |
| Payer reports | Plan-level benchmarks and published requirements | Different scopes, timing, and definitions | Payer review and trend comparison |
| Clearinghouse or RCM platform | Broad service and revenue linkage | Authorization status may lag or be incomplete | Financial and denial-cost analysis |
| Care-coordination SaaS | Cross-workflow status and patient-experience context | Integration quality and proxy data can distort results | Unified monitoring and escalation |

## Common Measurement Mistakes and How to Avoid Them
One common mistake is comparing insurers with incompatible product lines or service categories. A behavioral health organization, oncology network, and home-health agency should not be judged by the same raw rate without considering case complexity and benefit design. Another is treating returned requests as payer denials, which understates substantive denial performance and overstates appeal eligibility. Some teams also count a resubmission as a new request, artificially increasing volume and changing the rate. Deduplication should be based on the payer authorization number, patient, service, and episode, with a documented exception for genuinely separate services.

A further error is reporting only the average. Long waits can be hidden by many rapid decisions, so median and 90th-percentile turnaround times are more informative. Teams must also avoid excluding requests for which the payer never issued a decision, because those cases may represent serious operational or patient-safety risk. Month-end snapshots can understate aging work, making a rolling weekly report preferable. Finally, clinics should not use denial rates to rank individual clinicians without reviewing case mix and documentation. The metric is a system signal, not a simple productivity score.

Data quality controls should include monthly reconciliation, duplicate testing, missing-date monitoring, and review of outliers. A reasonable completeness target is at least 98% of records with a unique request identifier, payer, service, submission date, and status. Cases without a decision date should be separated from completed denials, and unknown reason codes should remain visible rather than being silently assigned to “other.” A quarterly audit of at least 30 cases, or all cases if volume is lower, can test whether staff apply the definitions consistently. Corrections should be documented, and historical metrics may need restatement when a definition changes.

## When to Act on a High Denial Metric

Escalation should depend on the rate, the pattern, the severity, and the availability of evidence. A clinic should act during the same week when a denial threatens an urgent or time-sensitive treatment, a required appeal deadline is within seven days, or a payer repeatedly fails to respond. For nonurgent trends, investigate within 30 days if the denial rate rises by 5 percentage points over a rolling quarter, remains 5 points above the network baseline for two periods, or affects a growing number of patients. A single isolated denial generally calls for case management, not a payer-level corrective action.

A root-cause review should use a small Pareto analysis of denial reasons, identifying the categories responsible for most avoidable losses. The team can then test an intervention for 60 to 90 days, such as revised checklists, targeted coder education, improved payer-rule content, or escalation of a disputed policy. It should compare both the target reason and total staff hours per approved authorization. If a service generates fewer denials but consumes dramatically more work, a narrow rate improvement may not justify the added expense. Conversely, a lower denial rate may be unacceptable if patients experience dangerous delays or abandon care.

## What Prior Authorization Analytics May Cost

Pricing varies by the clinic’s size, existing systems, number of payers, and whether the product is a stand-alone tool or part of a broader revenue-cycle platform. Small clinics may find spreadsheet-based tracking and payer checklist subscriptions adequate, while regional networks often pay for interfaces, workflow automation, analytics, implementation, and support. Enterprise deployments can involve contract, integration, security, and professional-services fees that are not comparable with the base software subscription. Because no responsible universal price can be inferred from the available research, a buyer should request a total-cost proposal that separates implementation, per-user or per-facility fees, interface charges, data storage, support, and renewal increases.

The business case should be calculated from the organization’s own data. A basic model multiplies preventable denials by average staff time, rework cost, avoidable administrative expense, delayed-payment impact, and measured appeal cost. It should use a conservative recoverable percentage rather than assume every denial can be eliminated. For example, if a network handles 10,000 decisions annually, has a 15% denial rate, and can prevent one-fifth of those denials through better submission work, the gross reduction would be 300 cases before considering appeals or newly submitted requests. That calculation is a scenario, not a guaranteed saving, and should be updated with actual staffing, denial mix, and payer response data.

The best solution is therefore the one that produces reliable definitions, actionable reasons, timely escalation, and measurable improvements. getpulse.care’s care-coordination angle can support clinics that want to connect authorization performance with patient communication and operational monitoring, but the priority remains trustworthy data. Organizations should begin with a small service line, establish baseline metrics, reconcile results, and expand only after staff use the reports in real decisions.

## Quick answers

### What is a good prior authorization denial rate for a clinic?

There is no single good rate for every clinic. KFF reported that certain insurers denied approximately 12% to 18% of measured requests in 2025, but service mix, payer, benefit design, and data definitions matter. Compare results with the clinic’s own baseline and comparable service lines rather than treating that range as a universal target.

### What is the most important prior authorization metric beyond denial rate?

The appeal overturn rate is one of the most important companion measures because it helps identify initial-review errors and documentation gaps. It should be paired with appeal filing rate, final denial rate, turnaround time, and patient delay measures so that a high overturn rate is not mistaken for the clinic’s only goal.

### How often should a care network review prior authorization denial metrics?

Operational teams should review open cases weekly and analyze payer and service-line trends monthly. A quarterly root-cause review can test whether checklist, training, or process changes are working, while urgent or deadline-sensitive cases should be handled immediately.

### Are administrative returns the same as payer denials?

No. An administrative return may occur because a submission is missing a document, code, or required field, and it may never reach a payer’s clinical decision. Clinics should report returned submissions separately from substantive denials while tracking how many ultimately result in denial after correction.

### Can patient-experience data be connected to prior authorization denial metrics?

Yes, with appropriate privacy controls and reliable linkage between authorization and patient-communication systems. Clinics can track delayed-treatment reports, abandoned cases, complaints, and care-plan changes by authorization outcome, but correlation should not be presented as proof that the authorization process caused the patient’s condition or experience.

Canonical: https://getpulse.care/knowledge/how_should_clinics_measure_prior_authorization_denial_metrics_in_2026.php
Markdown: https://getpulse.care/knowledge/how_should_clinics_measure_prior_authorization_denial_metrics_in_2026.php/index.md